Literature DB >> 8120390

Coordinate regulation of multiple human lymphokine genes by Oct-1 and potentially novel 45 and 43 kDa polypeptides.

K Kaushansky1, S G Shoemaker, C A O'Rork, J M McCarty.   

Abstract

The hematologic response to inflammation is critically dependent on the release of a family of glycoproteins termed CSFs. Central to this process is the coordinated T lymphocyte production of three of these proteins, granulocyte macrophage-CSF (GM-CSF), IL-3, and IL-5. In the course of our studies of the transcriptional regulation of IL-3 expression we noted that the same or similar proteins that bound to the downstream-activating region of the human IL-3 gene were also captured using DNA probes derived from sequences present in the GM-CSF and IL-5 genes. In this study, DNA-protein cross-linking techniques and reporter gene analyses were used to define the nuclear proteins that mediate transcriptional enhancement of these genes at one cis-acting site. These studies establish that Oct-1, a member of the POU family of transcription factors, binds to regions of the GM-CSF, IL-3, and IL-5 promoters and contributes to basal T cell gene transcription. In addition, although the c-jun proto-oncogene product was detected in stimulated human T cells, two additional T cell-specific proteins (45 and 43 kDa) bind to the GM-CSF, IL-3, and IL-5 promoters and are functionally and immunologically distinct from c-jun or OAP40 (jun-D). These proteins contribute to transcriptional enhancement of the IL-3 and GM-CSF genes in stimulated T cells. Together, these data suggest that the coordinate regulation of several lymphokine genes is based on responses to shared proteins. These studies further our understanding of the networks of transcriptionally active proteins responsible for the host response to inflammatory stimuli.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8120390

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  DNase I footprinting of the human interleukin-5 gene promoter.

Authors:  D J Cousins; D Richards; D M Kemeny; S Romagnani; T H Lee; D Z Staynov
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

2.  Oct1 is a switchable, bipotential stabilizer of repressed and inducible transcriptional states.

Authors:  Arvind Shakya; Jinsuk Kang; Jeffrey Chumley; Matthew A Williams; Dean Tantin
Journal:  J Biol Chem       Date:  2010-11-04       Impact factor: 5.157

Review 3.  The Oct1 transcription factor and epithelial malignancies: Old protein learns new tricks.

Authors:  Karina Vázquez-Arreguín; Dean Tantin
Journal:  Biochim Biophys Acta       Date:  2016-02-10

4.  Conformational alteration of Oct-1 upon DNA binding dictates selectivity in differential interactions with related transcriptional coactivators.

Authors:  V Misra; S Walter; P Yang; S Hayes; P O'Hare
Journal:  Mol Cell Biol       Date:  1996-08       Impact factor: 4.272

5.  Modulation of cystic fibrosis lung disease by variants in interleukin-8.

Authors:  A D Hillian; D Londono; J M Dunn; K A B Goddard; R G Pace; M R Knowles; M L Drumm
Journal:  Genes Immun       Date:  2008-06-19       Impact factor: 2.676

6.  Multiple core homeodomain binding motifs differentially contribute to transcriptional activity of the murine gonadotropin-releasing hormone receptor gene promoter.

Authors:  Clay A Lents; Todd A Farmerie; Brian D Cherrington; Colin M Clay
Journal:  Endocrine       Date:  2009-03-31       Impact factor: 3.633

7.  Oct1 and OCA-B are selectively required for CD4 memory T cell function.

Authors:  Arvind Shakya; Alon Goren; Alex Shalek; Cody N German; Jeremy Snook; Vijay K Kuchroo; Nir Yosef; Raymond C Chan; Aviv Regev; Matthew A Williams; Dean Tantin
Journal:  J Exp Med       Date:  2015-10-19       Impact factor: 14.307

8.  The regulatory interplay between Oct-1 isoforms contributes to hematopoiesis and the isoforms imbalance correlates with a malignant transformation of B cells.

Authors:  Elizaveta V Pankratova; Alexander G Stepchenko; Irina D Krylova; Tatiana N Portseva; Sofia G Georgieva
Journal:  Oncotarget       Date:  2018-07-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.